EAGAN, Minn.--(BUSINESS WIRE)--Imprime PGG™, an investigational new drug from Biothera that enhances the innate immune system response, increases the effectiveness of Avastin® (bevacizumab) to kill cancer cells, according to new preclinical research presented yesterday at the 2007 American Society of Clinical Oncology Annual Meeting in Chicago.
Researchers at the Brown Cancer Center, University of Louisville, Kentucky, studied the synergistic effects of Imprime PGG in combination with Avastin in a xenograft mouse model where human ovarian cancer cells were implanted into the mice. In the treatment group receiving both Imprime PGG and Avastin, 86% of the mice survived 100 days compared with only 43% in the group receiving Avastin alone.
